🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shanghai Institute Of Biological Products clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Shanghai Institute Of Biological Products as lead sponsor. Synced 26 Sep 2026
13Current trials
11Recruiting now
5Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shanghai Institute Of Biological Products is the lead sponsor of 13 current clinical trials in our China register. 11 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Influenza virus split vaccine, Nirsevimab and SIBP-A16. The most-studied condition is Respiratory Syncytial Virus (RSV).

ClinicalTrials.gov trials by status

  • Recruiting1185%
  • Not yet open215%

Trials by phase

  • Phase 1862%
  • Phase 1/2215%
  • Phase 2215%
  • Phase EARLY_PHASE118%
01

Clinical trials sponsored by Shanghai Institute Of Biological Products

13 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Clinical Trial of SIBP-A16 Injection in Healthy Adults
NCT07106918 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus (RSV)
Phase EARLY_PHASE1 Recruiting 2025-08 China
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
NCT06990464 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1 Recruiting 2025-06 China
A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
NCT06771479 · ClinicalTrials.gov ↗ · Monkeypox
Phase 1 Recruiting 2025-01 China
A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.
NCT07205198 · ClinicalTrials.gov ↗ · Advanced Tumors
Phase 1 Recruiting 2025-10 China
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
NCT06298058 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2024-05 China
A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
NCT06985368 · ClinicalTrials.gov ↗ · Solid Tumor Malignancy
Phase 1 Recruiting 2025-06 China
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
NCT06932523 · ClinicalTrials.gov ↗ · Herpes Zoster (HZ)
Drug: Shingrix
Phase 1/2 Recruiting 2025-04 China
A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
NCT06512116 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2024-07 China
A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
NCT07302256 · ClinicalTrials.gov ↗ · Influenza
Phase 1 Recruiting 2025-12 China
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
NCT06194656 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting 2024-09 China
A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.
NCT06298071 · ClinicalTrials.gov ↗ · Gout
Phase 1 Recruiting 2023-03 China
Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants
NCT07363837 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus (RSV)
Phase 1/2 Not yet open 2026-01 China
Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
NCT07327398 · ClinicalTrials.gov ↗ · Influenza
Phase 2 Not yet open 2026-01 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanghai Institute Of Biological Products trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanghai Institute Of Biological Products trials

10 conditions
Respiratory Syncytial Virus (RSV)2Advanced Solid Tumor2Influenza2Advanced Solid Tumors1Monkeypox1Advanced Tumors1Solid Tumor Malignancy1Herpes Zoster (HZ)1Head and Neck Squamous Cell Carcinoma1Gout1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1311

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Respiratory Syncytial Virus (RSV)

SponsorTrials
Beijing Youcare Kechuang Pharmaceutical Technology2
MAXVAX Biotechnology Limited Liability Company2

Sponsors with the most current trials registered for this condition.

06

Questions about Shanghai Institute Of Biological Products trials

How many clinical trials does Shanghai Institute Of Biological Products sponsor?

Shanghai Institute Of Biological Products is the lead sponsor of 13 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Institute Of Biological Products trials recruiting?

Yes. 11 of its 13 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Institute Of Biological Products testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Influenza virus split vaccine (2), Nirsevimab (2), SIBP-A16 (2), Methotrexate (1) and Shingrix (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.